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Buccal drug delivery technologies for patient-centred treatment of    









dry	 mouth	 (xerostomia)	 because	 of	 radiation-induced	 damage	 to	 their	 salivary	 glands.	 Patients	 with	
xerostomia	suffer	 symptoms	 that	 severely	affect	 their	health	as	well	as	physical,	 social	and	emotional	
aspects	of	 their	 life.	The	current	management	of	 xerostomia	 is	 the	application	of	 saliva	 substitutes	or	
systemic	 delivery	 of	 saliva-stimulating	 cholinergic	 agents,	 including	 pilocarpine,	 cevimeline	 or	
bethanechol	 tablets.	 It	 is	 almost	 impossible	 for	 substitutes	 to	 replicate	 all	 the	 functional	 and	 sensory	
facets	of	natural	saliva.	Salivary	stimulants	are	a	better	treatment	option	than	saliva	substitutes	as	the	
former	 induce	 the	 secretion	 of	 natural	 saliva	 from	 undamaged	 glands;	 typically,	 these	 are	 the	minor	
salivary	 glands.	 However,	 patients	 taking	 cholinergic	 agents	 systemically	 experience	 pharmacology-
related	side	effects	including	sweating,	excessive	lacrimation	and	gastrointestinal	tract	distresses.	Local	
delivery	 direct	 to	 the	 buccal	 mucosa	 has	 the	 potential	 to	 provide	 rapid	 onset	 of	 drug	 action,	 i.e.	
activation	of	minor	salivary	glands	within	the	buccal	mucosa,	while	sparing	systemic	drug	exposure	and	
off-target	 effects.	 This	 critical	 review	 of	 the	 technologies	 for	 the	 local	 delivery	 of	 saliva-stimulating	
agents	includes	oral	disintegrating	tablets	(ODTs),	oral	disintegrating	films,	medicated	chewing	gums	and	
implantable	drug	delivery	devices.	Our	analysis	makes	a	strong	case	for	the	development	of	ODTs	for	the	





















1.1  Radiation-induced xerostomia (dry mouth) 
Head	and	neck	cancer	 is	a	general	 term	that	 includes	cancers	of	oral	cavity,	pharynx,	nasal	cavity	and	
larynx.	In	the	UK,	the	average	national	incidence	of	the	head	and	neck	cancer	was	19.2	per	100,000	of	
the	population	(Cancer	Research	UK	A),	and	the	majority	of	this	population	is	diagnosed	with	head	and	
neck	 cancer	 at	 the	 age	 of	 60	 to	 69	 years	 old	 (Cancer	 Research	 UK	 B).	 The	 most	 commonly	 used	
treatments	 for	 patients	with	 head	 and	 neck	 cancers	 are	 radiotherapy,	 chemotherapy,	 and	 surgery	 or	
combination	of	these	approaches.	Salivary	gland	damage	occurs	in	95%	to	100%	of	patients	treated	with	
radiotherapy,	which	leads	to	the	development	of	xerostomia	(Chambers	et	al.,	2004).	Xerostomia	is	the	
subjective	 feeling	of	dry	mouth	which	may	exist	as	a	consequence	of	 reduced	salivary	 flow	(Cassolato	
and	Turnbull,	2003).	Head	and	Neck	cancer	patients	not	only	suffer	from	oral	distress	but	other	clinical	
complications	 such	 as	 malnutrition,	 dental	 problems,	 and	 depression,	 not	 surprisingly,	 all	 of	 these	
compromise	the	quality	of	the	patient’s	life	(Chambers	et	al.,	2004).		
This	 review	 aims	 to	 investigate	 whether	 improvements	 to	 the	 formulations	 currently	 used	 to	 treat	
radiation-induced	 xerostomia	 are	 possible.	 The	 review	 critically	 evaluates	 the	 current	 options	 for	 the	
treatment	 of	 radiation-induced	 xerostomia	 and	 advocates	 local	 administration	 of	 saliva-stimulating	
agents	to	the	buccal	region.	Our	evaluation	recognises	that	any	product	for	delivering	drugs	to	stimulate	
the	 secretion	 of	 saliva	 should	 be	 designed	 in	 accordance	 with	 the	 principles	 of	 patient-centred	
medicines,	i.e.	with	patient	requirements	at	the	core	of	the	design.		
	
1.2  Sal iva and sal ivation 
Saliva	 is	 a	 very	 complex	 fluid;	 water	 forms	 the	 main	 fraction	 combined	 with	 electrolytes,	 minerals,	
buffers,	growth	factors,	enzymes,	cytokines,	proteins,	and	immunoglobulins	(Amerongen	and	Veerman,	
2002).	 These	 components	 are	 vital	 in	 maintaining	 oral	 homoeostasis	 that	 includes	 good	 oral	 health,	









The	minor	 salivary	 glands	 are	 600	 to	 1000	 glands	 distributed	 throughout	 the	 oral	 cavity,	 in	 the	 sub-
mucosal	 layer	 beneath	 the	 oral	 mucosal	 surface,	 with	 greatest	 density	 in	 the	 buccal	 cavity	 and	 lips	
(Dodds	et	al.,	2005;	Wang	et	al.,	2015).	Although	90%	of	the	average	daily	salivary	secretion,	1	to	1.5	L,	is	
produced	by	major	salivary	glands,	the	minor	salivary	glands	spontaneously	produce	around	10%	of	the	
total	 average	 of	 salivary	 secretions	 (Sonesson	 et	 al.,	 2003).	 Minor	 salivary	 glands	 produce	 salivary	
secretion	that	is	rich	with	mucin	protein	which	protects	the	oral	mucosa	from	dryness	(Sonesson	et	al.,	
2003).	For	the	major	salivary	glands,	the	unstimulated	salivary	flow	average	is	0.3	mL/min	(Amerongen	


















salivary	 glands	 are	 innervated	 by	 both	 sympathetic	 and	 parasympathetic	 nervous	 system	 stimulants,	
while	 the	 minor	 salivary	 glands	 are	 supplied	 with	 little	 or	 no	 sympathetic	 innervations	 (Proctor	 and	
Carpenter,	 2007).	 Salivary	 production	 is	 mediated	 through	 the	 binding	 of	 sympathetic	 and	
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parasympathetic	 neurotransmitters	 to	 their	 receptors.	 Acetylcholine	 is	 the	 parasympathetic	
neurotransmitter	 that	 binds	 to	 five	 subtypes	 the	muscarinic	 receptors,	M1-M5	 (Gautam	et	 al.,	 2004).	
Knockout	gene	experiments	using	mutant	mice	revealed	that	M1	and	M3	control	of	salivary	secretion	




1.3  Radiation-induced xerostomia 
The	 standard	 treatment	 plan	 for	 patients	 diagnosed	 with	 head	 or	 neck	 cancer	 is	 radiation	 therapy	
usually	combined	with	surgery	and/or	chemotherapy	(Yom,	2015).	The	major	salivary	glands	are	more	
externally	 located	 with	 respect	 to	 most	 of	 the	 tumours	 attributed	 to	 head	 and	 neck	 cancer	 and	
therefore	 are	 usually	 present	 in	 the	 fields	 of	 radiation	 exposure	 (Vissink	 et	 al.,	 2015a).	 Different	
treatment	 procedures	 are	 available	 to	 treat	 patients	 with	 head	 and	 neck	 cancer.	 Conventional	
radiotherapy	 (RT)	 and	 intensity-modulated	 radiotherapy	 (IMRT)	 are	 among	 these	 strategies,	 and	 they	
affect	salivary	glands’	hypofunction	and	thus	affect	the	prevalence	of	xerostomia.	Several	studies	have	
shown	that	salivary	function	and	salivary	flow	rate	are	better	preserved	when	using	 IMRT	(Tribius	and	
Bergelt,	 2011).	 For	 example,	 patients	 reported	 less	 severe	 xerostomia	 when	 treated	 with	 IMRT	 in	
comparison	to	conventional	RT	(Michael	et	al.,	2007).	The	severity	of	xerostomia	was	39.3%	vs	82.1%;	P	
=	0.001,	with	higher	stimulated	parotid	flow	rate	(0.90	mL/min	v	0.05	mL/min;	P	=	0.0001),	and	higher	
stimulated	 whole	 salivary	 flow	 rate	 (0.41	 mL/min	 v	 0.20	 mL/min;	 P	 =	 0.001)	 (Michael	 et	 al.,	 2007).	
Standardisation	of	the	total	amount	of	IMRT	dose	fractionation	for	head	and	neck	cancer	is	difficult,	as	
this	depends	on	the	extent	of	the	patient’s	tumour.	However,	a	typical	plan	 is	to	treat	patients	with	a	
total	 amount	 of	 radiotherapy	 between	 50	 to	 70	 gray	 (Gy).	 This	 is	 achieved	 by	 a	 daily	 fraction,	 for	
example	 2	 Gy,	 over	 a	 period	 of	 many	 weeks	 (Kean	 et	 al.,	 2009).	 Common	 changes	 observed	 in	 the	
salivary	glands	after	irradiation	treatment	are	degranulation	and	necrosis	of	the	acinar	cells	due	to	their	
membrane	damage,	as	well	as	chronic	 inflammation	and	fibrosis	of	the	gland	lobules,	especially	 in	the	
periductal	 and	 intraocular	 areas	 (Grundmann	 et	 al.,	 2009;	 Konings	 et	 al.,	 2005).	 As	 a	 result,	 a	 rapid	
decrease	of	up	to	50-60%	in	the	salivary	function	in	the	initial	phase	of	treatment,	if	the	radiation	passes	
through	 the	 major	 salivary	 glands	 (parotid,	 sublingual	 and	 submandibular).	 Upon	 completion	 of	 the	
treatment,	 	saliva	usually	falls	to	its	minimum	flow	rate	(Chambers	et	al.,	2004).	 In	healthy	individuals,	













during	 the	development	of	 radiation-induced	xerostomia.	For	example,	 there	are	noted	concentration	
increases	in	sodium,	calcium,	magnesium	and	chloride	ion	(table	1)	which	are	all	dependent	on	salivary	
flow	rate	(Pinna	et	al.,	2015).	Radiation	treatment	also	contributes	to	a	decrease	 in	saliva	bicarbonate	
concentration,	and	 this	affects	buffer	 capacity.	These	changes	are	 related	 to	damage	 to	 the	 secretory	
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Table	 1:	 The	 concentration	 of	 saliva	 components	 before	 and	 after	 radiation	 treatment.	 Table	 adapted	 from	 (Dreizen	 et	 al.,	
1976),	a	study	carried	out	with	samples	of	stimulated	whole	saliva	of	30	patients	with	head	or	neck	tumours.	This	table	also	
includes	the	result	of	the	analysis	of	39	patients	who	were	diagnosed	with	nasopharyngeal	carcinoma,	(Pow	et	al.,	2016).	Data	
collection	 points	 were	 every	 3,	 6	 and	 12	 months.	 The	 table	 illustrates	 the	 six	 months’	 data	 average.	 Based	 on	 the	
concentrations	of	the	saliva	components	listed	below,	the	estimated	salivary	ionic	strength	before	and	after	radiotherapy	is	88	
mmol	 and	 148	 mmol	 respectively.	 P	 or	 probability	 level	 of	 less	 than	 0.001	 indicates	 statistically	 significant	 changes	 in	 the	
measurements.	
Saliva components Before Radiotherapy (mEq/L) After Radiotherapy 
(mEq/L) 
P value 
Sodium (Na +)  38.42	 78.27	 <0.001	
Calc ium (Ca 2+)  1.51	 2.80	 >0.05	
Magnesium (Mg 2+)  0.37	 0.99	 <	0.001	
Chloride (Cl  -)  24.68	 45.03	 <	0.001	
Bicarbonate (HCO 3 
-)  19.80	 7.95	 <	0.001	
Nitrate (NO 3 
-)  0.21	 0.06	 0.015	
Sulphate (SO 4 
2-)  0.10	 0.22	 <	0.001	
Lactate (C 3H 6O 3 
-)  0.01	 0.15	 <	0.001	
Formate (CHO 2 
-)  0.01	 0.04	 0.011	
Propionate (C 3H 6O 2 
-)  0.05	 0.06	 Unknown	
Acetate (C 2H 3O 2 
-)  0.54	 0.59	 Unknown	
Thiocyanate (SCN -)  0.30	 0.06	 <	0.001	
	
1.4  Impact of xerostomia on health and quality of l i fe 
Abnormalities	which	affect	 the	quality	or	quantity	of	saliva	will	diminish	the	quality	of	 life	of	patients.	
The	quality	 of	 life	 is	 defined	 as	 “the	 assessment	 of	 an	 individual’s	well-being,	 including	 all	 emotional,	
social	and	physical	aspects”	 (Dirix	et	al.,	2008).	Oral	 cavity	dryness,	 inflammations,	and	ulcers	 start	 to	
appear	 at	 the	 early	 stages	 of	 xerostomia,	which	 translates	 into	 difficulties	 in	 speech	 and	 swallowing.	
Difficulties	 in	speaking	affect	patients’	ability	 to	communicate	and	work.	Moreover,	any	change	 in	 the	
saliva	quality	will	 lead	to	a	reduction	 in	the	number	of	taste	buds	(Henkin	et	al.,	1972).	Thus,	patients	
with	xerostomia	will	experience	a	reduction	of	nutritional	intake	that	will	lead	to	significant	weight	loss	











by	either	using	 salivary	 substitutes	when	 salivary	 glands	 are	 completely	 damaged	or	by	using	 salivary	
stimulants	when	there	is	residual	salivary	gland	function.	
	
2.1   Sal ivary substitutes 
Salivary	substitutes,	for	example,	water,	milk	and	artificial	saliva,	are	used	to	provide	lubrication	and	to	
moisturise	the	oral	cavity	surface	and	therefore	relieve	the	sensation	of	dryness.	 It	has	been	reported	
that	 frequent	 sips	 of	 water	 are	 effective	 in	 dry	 mouth	 management.	 Moreover,	 using	 milk	 was	 also	
found	 to	 be	 beneficial	 as	 it	 contains	 chemical	 constituents	 that	 contribute	 towards	 lubrication,	




action,	 taste,	 delivery	 system	 and	 price	 of	 the	 product.	 The	 first	 generation	 of	 artificial	 liquid	 saliva	
































































































Owing	 to	 the	biochemical	 complexity	of	 natural	 saliva	 (fig	 2),	 no	 salivary	 substitute	 can	match	 all	 the	
physio-chemical	 parameters	 of	 it	 (Samarawickrama,	 2002).	 Furthermore,	 the	 efficacy	 of	 a	 saliva	
substitute	is	also	dependent	on	the	guidance	that	is	given	to	the	patient,	e.g.	when	to	apply	and	what	
product	to	use.	The	manufacturer	provides	instructions	for	the	use	of	each	artificial	saliva	product	and	
non-compliance	 with	 these	 instructions	 reduces	 the	 effectiveness	 of	 the	 salivary	 substitute.	 Patients	
should	use	different	products	based	on	the	severity	of	xerostomia	and	the	time	of	the	day.	For	example,	
in	 severe	 xerostomia,	 a	 gel-like	 salivary	 substitute	 should	 be	 used	 overnight,	 whereas	 a	 more	 liquid	
substitute	may	 be	more	 appropriate	 during	 the	 day	 (Regelink	 et	 al.,	 1989).	 Saliva	 substitutes	 have	 a	

































2.2  Sal ivary st imulants  
Cholinergic	 agents	 act	 through	 the	 parasympathetic	 nervous	 system	 and	 have	 been	 developed	 as	
salivary	stimulants	for	xerostomia.	These	drugs,	which	include	pilocarpine,	cevimeline,	and	bethanechol,	
induce	 the	 secretion	 of	 natural	 saliva	 from	 the	 undamaged	 part	 of	 the	 salivary	 glands	 through	 their	
action	on	muscarinic	receptors	(Holmes,	1998;	Napeñas	et	al.,	2009).	
	
Salagen®	 (a	 pilocarpine	 HCl	 tablet)	 is	 the	 only	 drug	 product	 for	 the	 treatment	 of	 radiation-induced	
xerostomia	that	has	been	approved	in	Europe	and	the	USA.		It	is	a	film-coated	tablet	that	contains	5	mg	
of	 pilocarpine	 HCl,	microcrystalline	 cellulose	 as	 a	 binder,	 stearic	 acid	 as	 a	 lubricant	 and	 acidifier	 and	
carnauba	wax	as	a	polishing	agent.	Pilocarpine	is	effective	not	only	in	radiation-induced	xerostomia	but	
also	 in	 diseases	 of	 the	 salivary	 glands	 such	 as	 Sjögren’s	 syndrome.	 Significant	 improvements	 to	 the	
symptoms	of	xerostomia	can	be	achieved	by	administering	5	mg	pilocarpine	 three	 times	a	day	over	a	
period	 of	 8	 to	 12	weeks	 (DuRant	 et	 al.,	 1993).	 The	maximum	prescribed	 dose	 of	 30	mg	 daily	 can	 be	
considered	for	patients	who	have	not	responded	to	the	fixed	dose	of	5	mg	three	times	daily	(Vissink	et	
al.,	 2015b).	 Pilocarpine	 can	 also	 be	 used	 as	 a	maintenance	 therapy	 during	more	 extended	 treatment	
periods	(Acobs	et	al.,	1996).	 	Peak	plasma	concentrations	of	15	and	41	µg/L	for	pilocarpine	have	been	
recorded	after	ingestion	of	5	mg	or	10	mg	tablets	three	times	a	day,	with	peak	concentrations	reached	
in	 75	 and	50	min	 after	 administration,	 respectively,	 (Guchelaar	 et	 al.,	 1997).	 Pilocarpine	 is	 eliminated	
mainly	in	the	urine	with	an	elimination	half-life	of	45	and	80	min	for	5	and	10	mg	doses,	respectively.	To	
avoid	rapid	elimination	and	maximise	exposure	at	the	site	of	action,	absorption	of	pilocarpine	into	the	
systemic	 system	 should	 be	 minimised,	 e.g.	 by	 local	 administration	 of	 lower	 doses	 direct	 to	 the	
undamaged	salivary	glands.	Sublingual	formulations	will	not	fulfil	this	design	brief	as	the	mucosa	in	this	



















et	 al.,	 2015).	 The	 feasibility	 of	 reformulating	 bethanechol	 has	 been	 investigated	 by	 introducing	 a	
saturated	 solution	 of	 the	 drug	 within	 the	 buccal	 cavity	 for	 a	 fixed	 period	 to	 test	 for	 salivary	 gland	
activation.	The	initial	results	were	encouraging,	but	issues	concerning	the	physical	and	chemical	stability	
of	the	saturated	solutions	must	be	resolved	for	this	apparently	simple	formulation	approach	to	succeed	
(Cotomacio	 et	 al.,	 2017).	 	 Although	 pilocarpine,	 cevimeline	 and	 bethanechol	 are	 all	 candidates	 for	
localised	 salivary	 stimulation	 therapy	 for	 radiation-induced	 xerostomia	 (Mercadante	 et	 al.,	 2017),	
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cevimeline	 is	 licensed	by	 the	FDA	only	 for	 the	 treatment	of	xerostomia	 related	 to	Sjögren’s	syndrome	
and	is	not	available	in	many	countries	(José-Antonio	et	al.,	2016).		In	contrast,	pilocarpine	is	indicated	for	
radiation-induced	 xerostomia	 and	 is	 widely	 available	 in	 most	 countries.	 This	 makes	 pilocarpine	 an	




















Limitations	 The	 limitations	 are	 due	 to	 the	 systematic	 exposure	 of	 the	 drug	
that	produce	off-target	effects	(side	effects)	via	stimulation	of	the	
parasympathetic	 nervous	 system.	 These	 include	 transient	
sweating,	flushing	or	warmth,	 increased	urinary	frequency,	nasal	
secretion,	lacrimation	and	gastrointestinal	tract	distress.	




The	 available	 products	 are	
simple	 and	 do	 not	mimic	 the	





Reformulate	 the	 products	 to	 achieve	 local	 therapeutic	 effect	 by	
local	activation	of	the	minor	salivary	glands.	
Design	 of	 a	 product	 that	




















































































































Since	 the	 function	 of	 minor	 salivary	 glands	 is	 preserved	 better	 than	 the	 major	 salivary	 glands	 post	
radiation	therapy,	 local	delivery	of	cholinergic	agents	provides	a	means	of	drug	targeting	to	the	saliva-
producing	minor	glands	 located	 just	below	the	oral	epithelium.	Advantages	of	buccal	mucosa	as	a	site	
for	 topical	 drug	 delivery	 include:	 (i)	 a	 robust	 nature,	 this	 oro-mucosa	 has	 short	 recovery	 times	 after	
stress	or	damage	(Gandhi	and	Robinson,	1994);	(ii)	the	absence	of	Langerhans	cells	which	offers	a	high	





systemic	 circulation	 	 associated	 with	 sublingual	 administration	 (Narang	 and	 Sharma,	 2011).		
Encouragingly,	 delivery	 of	 pilocarpine	 nitrate	 via	 the	 buccal	 mucosa	 in	 beagle	 dogs	 resulted	 in	 an	




should	 be	 utilised	 in	 the	 design	 of	 a	 pharmaceutical	 drug	 product.	 	 This	 approach	 can	 maximise	
therapeutic	 benefit,	 enhance	 patient	 adherence	 and	 aligns	 with	 the	 current	 paradigms	 for	 the	
development	of	more	patient-centred	medicines	(Stegemann	et	al.,	2016).		
	
3.1  Pharmaceutical  dosage forms and technologies 
A	range	of	pharmaceutical	dosage	forms	and	technologies	may	be	utilised	to	deliver	pilocarpine	to	the	





excipients	 and	 taste	 masking	 agents,	 (if	 included),	 must	 be	 compatible	 with	 the	 drug	 and	 the	
administered	product	should	leave	little	or	no	solid	residue	(Slavkova	and	Breitkreutz,	2015).	
	
3.1.1 Orally disintegrating tablets 




in	 a	 small	 amount	 of	 saliva	within	 the	maximum	of	 3	minutes.	 Currently,	 the	 accepted	 disintegrating	
times	 for	ODTs	 range	between	2	and	30	seconds,	e.g.	Xilopar	Zydis®	 and	Calpol®fastmeltsFlashtab® 
(Pabari	 et	 al.,	 2012).	 The	 pharmacopoeia	 guidelines	 provide	 only	 partial	 guidance	 on	 the	 acceptable	
limits	 for	 the	 disintegration	 times	 of	 ODTs	 and	 these	 times	 are	 typically	 measured	 using	 technology	
design	 for	more	 traditional	oral	dosage	 forms	 (Food	and	Drug	Adminstration,	2008).	 	 In	 the	 case	of	 a	
new	 product	 designed	 for	 the	 delivery	 of	 cholinergic	 agents,	 salivary	 stimulation	 will	 be	 directly	
influenced	by	the	disintegration	time	of	the	ODT	product.	Disintegration	time	will	depend	on	the	tablet’s	
dimensions,	 weight,	 manufacturing	 technology	 and	 the	 method	 used	 to	 measure	 disintegration.	









especially	 conveys	 fast	 disintegration/dissolution	 when	 in	 the	 presence	 of	 small	 amount	 of	 aqueous	
media.	Addition	of	saccharides	also	induces	a	more	uniform	pore	size	in	ODTs	prepared	by	freeze	drying.		
A	 network	 of	 pores	 throughout	 the	 tablet	 allows	 the	 rapid	 water	 uptake.	 Sweeteners,	 pH	 adjusting	
substances	and	preservatives	can	also	be	included	in	ODTs	formulations	if	required	(Sastry	et	al.,	2000).	
	
A	 wide	 range	 of	 approaches	 and	 technologies	 are	 used	 to	 produce	 ODTs	with	 the	 primary	 goal	 of	 a	






long	 as	 the	 API	 underdevelopment	 has	 a	 high	 enough	 water	 solubility.	 Pilocarpine	 HCl	 fulfils	 these	




delivery,	 but	 it	 did	 lead	 to	 a	 viscous	 solution	 or	 gel	 upon	 disintegration,	 that	 was	 designed	 to	 keep	
naloxone	in	contact	with	the	buccal	mucosa	and	prevent	it	being	swallowed	by	the	patient,	(Alqurshi	et	





the	 desired	 product.	 However,	 the	 resulting	 tablets	 tend	 to	 be	 quite	 brittle,	 thus	 moulding	 and	
compression	manufacturing	methods	 increase	 the	 chance	 of	 breakage	 of	 the	 tablets	 during	 handling	
when	 the	 blister	 packaging	 is	 opened	 (Badgujar	 and	 Mundada,	 2011).	 Compression	 methods	 are	
commonly	used	in	pharmaceutical	 industry	due	to	the	low	costs	of	production.	However,	compression	
procedures	 are	 not	 designed	 to	 meet	 the	 specifications	 for	 fast	 disintegrating	 tablets,	 such	 as	 a	
sufficiently	high	porosity	of	20%	or	above,	which	is	crucial	for	rapid	disintegration	(Koseki	et	al.,	2009).		
	
The	 inclusion	 of	 super	 disintegrants,	 for	 example,	 sodium	 starch	 glycolate,	 can	 improve	 the	
disintegration	 times	 for	 the	 relatively	hard	 tablets	produced	by	 compression.	 For	 example,	Nurofen®	
Meltlets	produced	by	dry	granulation	and	compression,	containing	200mg	of	ibuprofen,	disintegrate	in	





3.1.2 Orally disintegrating f i lms  
ODFs	are	dosage	forms	which	also	quickly	dissolve,	disintegrate	or	melt	inside	a	patient’s	mouth	without	
chewing	and	water	 intake	 (Moqbel	et	al.,	2016).	A	typical	ODF	formulation	contains	 in	addition	to	the	
active	 pharmaceutical	 ingredient,	 a	 hydrophilic	 polymer,	 a	 plasticiser,	 a	 filler	 and	 a	 flavouring	 agent	










Casting	 (solvent	 and	 semi-solid	 casting),	 extrusion	 (hot	 melt	 and	 solid	 dispersion)	 and	 rolling	 are	
methods	 for	 manufacturing	 ODFs.	 Solvent	 casting	 is	 the	 most	 commonly	 used	 method	 as	 it	 is	
straightforward	 and	 easy.	 However,	 ODFs	 prepared	 by	 the	 solvent	 casting	 method	 have	 the	
disadvantages	 of	 limited	 production	 capacity,	 environmental	 concerns,	 and	 instability	 generated	 by	
unpredictable	 factors	 such	 as	 polymer	 chain	 relaxation,	 moisture	 absorption	 or	 loss,	 and	 polymer-
plasticizer	 interaction	during	storage	 (Low	et	al.,	2013).	Hot-melt	extrusion	has	 the	advantage	of	both	
simplicity	 and	 high	 production	 capacity	 and	 is	 often	 used	 to	 enhance	 the	 solubility	 of	 poorly	 soluble	




been	 fabricated	 as	 a	 sublingual	 film	 and	 proven	 effective	 for	 the	 treatment	 of	 Sjögren’s	 syndrome	
(Rodríguez-Pulido	et	al.,	2017),	but	has	not	been	evaluated	in	radiation-induced	xerostomia.	
	








carbamide	 (Mehring	 and	Waukesha,	 1997;	 Valoti.	 et	 al.,	 2003).	 Therefore,	 it	 would	 be	 interesting	 to	
reformulate	 pilocarpine	 to	 locally	 activate	 the	minor	 salivary	 glands	 through	 direct	 absorption	 of	 the	
drug	into	the	buccal	mucosal	tissues	from	a	gum	base.		
	
For	 successful	medicated	 chewing	gum,	 the	manufacturing	method	 should	be	able	 to	deliver	5	mg	of	
pilocarpine	without	the	need	of	water	and	with	a	pleasant	mouth	feel.	The	manufactured	chewing	gum	
should	be	stable	 towards	humidity	and	 temperature	changes.	Water	 soluble	and	water-insoluble	gum	
bases	 are	 the	 typical	 composition	 of	 a	 medicated	 chewing	 gum,	 (table	 6).	 There	 are	 two	 types	 of	
manufacturing	methods	 available	 for	manufacturing	medicated	 chewing	 gums	namely,	 the	 traditional	







affected	 by	 many	 different	 factors.	 For	 example,	 the	 aqueous	 solubility	 of	 the	 drug	 influences	 the	
release	rate,	as	the	gum	must	be	hydrated	by	saliva	for	the	drug	to	dissolve	and	then	diffuse	through	the	
action	 of	 chewing	 (Maggi	 et	 al.,	 2005).	 Moreover,	 the	 drug	 release	 from	 the	 chewing	 gum	 is	 also	
controlled	by	the	contact	time,	chewing	time,	intensity	and	rate,	which	can	vary	between	patients.	The	
European	Pharmacopeia	suggested	that	60	chews/min	is	the	average	rate	to	release	an	active	ingredient	
from	 a	 gum	 (Pharmacopia,	 2005).	 More	 generally,	 patients	 with	 dry	 mouth	 may	 struggle	 to	 use	 a	
chewing	gum,	with	the	crushing	of	the	gum’s	initially	un-wetted	and	hard	structure	causing	difficulties.	























Elastomers	 15-45%	 Provide	gum	with	rubbery	texture.	 Polyisobutylene,	
isobutylene.	
Rubber	 15%	 Softener	and	binding	agent.	 Glycerol	esters,	terpene	
resins.	






3.1.4 Implantable drug delivery devices 
Another	pharmaceutical	solution	is	to	build	an	oral	device	and	implant	this	into	a	prosthetic	tooth	crown	
or	embed	inside	a	denture.	All	implantables	aim	to	reduce	the	frequency	of	drug	administration,	and	in	
doing	 so	 such	 devices	 permit	 site-specific	 drug	 administration	 and	 continual	 release	 of	 a	 therapeutic	
agent	(Scholz	et	al.,	2008).	Drug	release	from	implantable	drug	delivery	systems	may	achieve	both	local	
and	 prolonged	 drug	 release.	 Thus	 controlled	 release	 implants	 enhance	 the	 efficacy	 of	 the	 therapy,	




device	 should	 be	 biocompatible;	 it	 must	 be	 stable	 and	 withstand	 the	 harsh	 environment	 inside	 the	
mouth,	 such	 as	 high	 humidity,	 temperature	 variations,	 the	 force	 of	 mastication	 and	 salivary	 buffers.	
Additionally,	ease	of	manufacturing	and	relatively	low	product	costs	are	important.		
	
Implantable	 drug	 delivery	 technologies	 may	 be	 divided	 into	 non-degradable	 and	 degradable	 implant	
systems	 (Rajgor	 et	 al.,	 2011).	 The	 non-degradable	 systems	 include	 polymeric	 matrices	 reservoir-type	
devices	and	magnetically	controlled	platforms.	The	biodegradable	systems	have	the	advantage	of	using	
inert	 polymers	 that	 are	 eventually	 absorbed	 by	 the	 body.	 Thus,	 the	 design	 and	 development	 of	 such	
systems	are	more	complicated	 in	comparison	to	the	non-biodegradable	systems.	Designing	a	reservoir	




										Implantable	 systems	may	also	 contain	 small	electrodes	 that	 function	 to	 stimulate	 salivary	 flow.	Smidt	
and	Andy,	 2010	 evaluated	 the	 efficacy	 of	 an	 electro-stimulation	device	 as	 a	 fixed	 implant	 for	 salivary	
secretion.	The	main	purpose	of	their	approach	was	to	stimulate	the	secretion	of	natural	saliva	over	an	
extended	period	using	the	implanted	electrodes.	This	was	accomplished	by	electrical	stimulation	of	the	
long	 buccal	 nerve	 and	 lingual	 nerve,	 through	 an	 artificial	 dental	 implant.	 The	 price	 of	 such	 devices	 is	
expected	 to	 be	 high	 and	 thus	will	 not	 be	 an	 option	 for	 all	 patients.	 Furthermore,	 this	 class	 of	 device	
requires	 regular	maintenance	as	 it	 contains	a	battery	 that	needs	 to	be	 replaced,	microprocessors	and	
sensors	which	all	require	removal	of	the	implant	if	they	fail.	
4 Patient	centric	pharmaceutical	drug	product	design		
Consideration	 of	 the	 patient-medicine	 interface	 is	 essential	 during	 the	 design	 of	 any	 pharmaceutical	
formulation	where	 the	patient’s	needs	are	at	 the	 core	of	 the	design.	 Therefore,	 improvements	 in	 the	
delivery	of	salivary	stimulants	must	be	designed	based	on	the	information	available	regarding	the	needs	






delivery	 devices	 are	 expensive	 and	 poorly	 responsive	 to	 a	 sudden	 change	 in	 the	 patient’s	 needs	 for	
example	when	eating	a	meal.	In	addition,	most	of	the	patients	with	radiation-induced	xerostomia	have	
dental	decay	and	mucosal	sensitivity	(Murphy	et	al.,	2007).	Therefore,	attaching	an	 implant	within	the	
mouth	may	be	problematic	 as	 decay	 leads	 to	 an	unstable	dental	 architecture	 and	patients’	 increased	
sensitivity	 to	 foreign	objects	will	 reduce	adherence.	For	medicated	chewing	gum,	 saliva	 is	 required	 to	










possibility	 that	 the	patients	may	accidentally	 swallow	 these	medicines	before	 they	are	 fully	dispersed	
and	 the	 drug	 is	 released.	 However,	 this	 issue	 may	 be	 addressed	 by	 achieving	 extremely	 rapid	
disintegration	of	the	formulation	or	using	specific	excipients	to	keep	the	drug	located	on	the	surface	of	
the	buccal	mucosa.	Orally	disintegrated	tablets	quickly	disintegrate	with	minimal	effort	and	without	the	
need	 of	 water,	 therefore,	 this	 dosage	 form	 perfectly	 suits	 elderly	 patients	 diagnosed	 with	 radiation-
induced	xerostomia	where	dysphagia	 is	one	of	 the	most	common	symptoms	of	 the	condition.	A	study	
conducted	 by	 Liu	 et	 al.,	 (2016)	 found	 that	 elderly	 people	 with	 dysphagia	 prefer	 orally	 disintegrating	
tablets	 over	 other	 pharmaceutical	 dosage	 forms	 such	 as	 chewing	 gums,	 mini	 tablets	 and	 dispersible	
tablets.	Therefore,	delivering	the	pilocarpine	using	an	orally	disintegrating	tablet	would	be	expected	to	
enhance	patient’s	adherence	to	the	medicine.	To	achieve	a	patient	centric	design,	an	ODT	used	for	the	
treatment	 of	 xerostomia	must	 be	 optimised	 for	 shape	 and	 size.	 These	 parameters	 should	match	 the	
dimensions	of	the	finger	print	area	of	the	thumb	in	order	to	ease	administration	and	attachment	to	the	
buccal	 area.	 In	 addition,	 patients	 with	 radiation-induced	 xerostomia	 might	 require	 a	 range	 of	
therapeutic	 doses	 based	 on	 the	 severity	 of	 dry	 mouth.	 Freeze	 drying	 plays	 a	 central	 role	 in	 the	
development	of	orally	disintegrating	tablets	whereby	the	dose	may	be	easily	adjusted	within	a	known	
design	 space,	 to	 meet	 patient’s	 needs	 by	 titrating	 different	 amounts	 of	 the	 active	 ingredient.	 Many	
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Xerostomia	 is	 common	 in	 head	 and	 neck	 cancer	 patients	 treated	 with	 radiotherapy.	 If	 untreated,	
xerostomia	 can	 cause	 complications	 including	 nutritional	 deficiencies,	 low	mood	 and	 depression.	 The	
current	 treatments	 for	 radiation-induced	 xerostomia	 are	 suboptimal.	 Pilocarpine,	 the	 only	
pharmacophore	 licensed	 to	 treat	 this	 condition,	 is	 beset	 by	 off-target	 side	 effects	 associated	 with	
cholinergic	 therapy.	 Local	 application	 to	 the	 buccal	 mucosa	 would	 have	 the	 advantages	 of	 ease	 of	
administration,	good	bioavailability	and	fast	onset	of	action.		Therefore,	reformulation	of	pilocarpine,	or	
other	 salivary	 stimulants,	 as	 a	 buccal	 formulation	 would	 be	 a	 significant	 step	 in	 improved	
pharmacotherapy	 of	 radiation-induced	 xerostomia.	 Fast	 disintegrating	 buccal	 tablets	 containing	
pilocarpine	 could	meet	 the	 needs	 of	 patients	with	 radiation-induced	 xerostomia	 including	 those	with	
dysphagia	 or	 benefitting	 from	 dose	 titration.	 Patient-centred	 pharmaceutical	 development	 would	
ensure	that	the	technology	is	designed	to	address	both	the	therapeutic	needs	and	the	lifestyle	of	those	
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